Healthcare Publications Mitochondrial myopathy diagnosis & treatment Marke

Mitochondrial myopathies are associated with mitochondrial diseases which are caused by
certain nuclear DNA deletions and mutations. Mitochondrial myopathies affect mitochondria
which is responsible for energy production within a cell associated with mitochondrial disease.
Thus, they cause low energy and free radical production which results in a variety of
symptoms.
The factors such as rising number of screening services for mitochondrial disorders, growing
number of mitochondrial myopathy cases, increased government funding and incentives for
rare genetic diseases are driving the market for mitochondrial myopathy diagnosis &
treatment. However, poor treatment options and absence of curative treatment have
constrained the market.
Considering all these factors, Mitochondrial Myopathy Diagnosis & Treatment Market is
expected to reach $ 33.6 million by the end of 2020, this market is projected to growing at a
CAGR of ~ 9.82 % during 2017-2020.
Key Findings:



Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes
(MELAS) and Progressive External Ophthalmoplegia (PEO) are the most commonly
found conditions in patients with mitochondrial myopathy. The global MELAS
diagnosis & treatment market is expected to grow at the CAGR of 19.39% during
2017 to 2020.
Genetic tests accounted for the largest market share in 2016, and is projected to
grow at a CAGR of 10.11% during 2017 to 2020.
Supportive therapy captured the whole market share in 2016, and is projected to
grow at a CAGR of 9.82% during 2017 to 2020.
Segments:
The Global Mitochondrial Myopathy Diagnosis & Treatment Market is segmented on the basis
of type, diagnostic tests and therapy. Based on type, the market has been segmented as
mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS),
progressive external ophthalmoplegia (PEO), myoclonic epilepsy with ragged red fibres
(MERRF), mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE), Kearns–
Sayre syndrome (KSS), mitochondrial DNA depletion syndrome (MDS), Pearson syndrome,
Leigh syndrome, neuropathy, ataxia, and retinitis pigmentosa (NARP). Based on the
diagnostic tests, the market has been segmented as genetic tests, muscle biopsy and
biochemical test. Based on the therapy, the market has been segmented as supportive
therapy and targeted therapy.
Key players of Global Mitochondrial myopathy diagnosis & treatment Market:
Key players profiled in the report are Centogene AG, GeneDx, Ixchel Pharma, Khondrion BV,
Mitobridge,
NeuroVive
Pharmaceutical
Biotherapeutics and others.
AB,
Reata
Pharmaceuticals
Inc.,
Stealth